243 related articles for article (PubMed ID: 15970553)
1. The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma.
Meier F; Schittek B; Busch S; Garbe C; Smalley K; Satyamoorthy K; Li G; Herlyn M
Front Biosci; 2005 Sep; 10():2986-3001. PubMed ID: 15970553
[TBL] [Abstract][Full Text] [Related]
2. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
3. Critical roles of Raf/MEK/ERK and PI3K/AKT signaling and inactivation of p38 MAP kinase in the differentiation and survival of monocyte-derived immature dendritic cells.
Xie J; Qian J; Yang J; Wang S; Freeman ME; Yi Q
Exp Hematol; 2005 May; 33(5):564-72. PubMed ID: 15850834
[TBL] [Abstract][Full Text] [Related]
4. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
[TBL] [Abstract][Full Text] [Related]
5. Human intestinal epithelial crypt cell survival and death: Complex modulations of Bcl-2 homologs by Fak, PI3-K/Akt-1, MEK/Erk, and p38 signaling pathways.
Harnois C; Demers MJ; Bouchard V; Vallée K; Gagné D; Fujita N; Tsuruo T; Vézina A; Beaulieu JF; Côté A; Vachon PH
J Cell Physiol; 2004 Feb; 198(2):209-22. PubMed ID: 14603523
[TBL] [Abstract][Full Text] [Related]
6. Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment.
Meier F; Busch S; Lasithiotakis K; Kulms D; Garbe C; Maczey E; Herlyn M; Schittek B
Br J Dermatol; 2007 Jun; 156(6):1204-13. PubMed ID: 17388918
[TBL] [Abstract][Full Text] [Related]
7. Opposite effects of Ha-Ras and Ki-Ras on radiation-induced apoptosis via differential activation of PI3K/Akt and Rac/p38 mitogen-activated protein kinase signaling pathways.
Choi JA; Park MT; Kang CM; Um HD; Bae S; Lee KH; Kim TH; Kim JH; Cho CK; Lee YS; Chung HY; Lee SJ
Oncogene; 2004 Jan; 23(1):9-20. PubMed ID: 14712206
[TBL] [Abstract][Full Text] [Related]
8. Computational Modeling of PI3K/AKT and MAPK Signaling Pathways in Melanoma Cancer.
Pappalardo F; Russo G; Candido S; Pennisi M; Cavalieri S; Motta S; McCubrey JA; Nicoletti F; Libra M
PLoS One; 2016; 11(3):e0152104. PubMed ID: 27015094
[TBL] [Abstract][Full Text] [Related]
9. Melanoma: molecular pathogenesis and emerging target therapies (Review).
Russo AE; Torrisi E; Bevelacqua Y; Perrotta R; Libra M; McCubrey JA; Spandidos DA; Stivala F; Malaponte G
Int J Oncol; 2009 Jun; 34(6):1481-9. PubMed ID: 19424565
[TBL] [Abstract][Full Text] [Related]
10. [Targeted molecular strategies for cancer therapy based on the blockage of oncogenic pathways in human tumor cells].
Ozaki K
Yakugaku Zasshi; 2007 Jun; 127(6):983-91. PubMed ID: 17541249
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen inhibits tumor cell invasion and metastasis in mouse melanoma through suppression of PKC/MEK/ERK and PKC/PI3K/Akt pathways.
Matsuoka H; Tsubaki M; Yamazoe Y; Ogaki M; Satou T; Itoh T; Kusunoki T; Nishida S
Exp Cell Res; 2009 Jul; 315(12):2022-32. PubMed ID: 19393235
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis suppression by Raf-1 and MEK1 requires MEK- and phosphatidylinositol 3-kinase-dependent signals.
von Gise A; Lorenz P; Wellbrock C; Hemmings B; Berberich-Siebelt F; Rapp UR; Troppmair J
Mol Cell Biol; 2001 Apr; 21(7):2324-36. PubMed ID: 11259582
[TBL] [Abstract][Full Text] [Related]
13. Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas.
Mawrin C; Sasse T; Kirches E; Kropf S; Schneider T; Grimm C; Pambor C; Vorwerk CK; Firsching R; Lendeckel U; Dietzmann K
Clin Cancer Res; 2005 Jun; 11(11):4074-82. PubMed ID: 15930342
[TBL] [Abstract][Full Text] [Related]
14. Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells.
Shelton JG; Steelman LS; Lee JT; Knapp SL; Blalock WL; Moye PW; Franklin RA; Pohnert SC; Mirza AM; McMahon M; McCubrey JA
Oncogene; 2003 Apr; 22(16):2478-92. PubMed ID: 12717425
[TBL] [Abstract][Full Text] [Related]
15. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
16. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells.
Lasithiotakis KG; Sinnberg TW; Schittek B; Flaherty KT; Kulms D; Maczey E; Garbe C; Meier FE
J Invest Dermatol; 2008 Aug; 128(8):2013-23. PubMed ID: 18323781
[TBL] [Abstract][Full Text] [Related]
17. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
[TBL] [Abstract][Full Text] [Related]
18. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Chappell WH; Abrams SL; Wong EW; Chang F; Lehmann B; Terrian DM; Milella M; Tafuri A; Stivala F; Libra M; Basecke J; Evangelisti C; Martelli AM; Franklin RA
Biochim Biophys Acta; 2007 Aug; 1773(8):1263-84. PubMed ID: 17126425
[TBL] [Abstract][Full Text] [Related]
19. Integrin β1, myosin light chain kinase and myosin IIA are required for activation of PI3K-AKT signaling following MEK inhibition in metastatic triple negative breast cancer.
Choi C; Kwon J; Lim S; Helfman DM
Oncotarget; 2016 Sep; 7(39):63466-63487. PubMed ID: 27563827
[TBL] [Abstract][Full Text] [Related]
20. Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia.
Blalock WL; Navolanic PM; Steelman LS; Shelton JG; Moye PW; Lee JT; Franklin RA; Mirza A; McMahon M; White MK; McCubrey JA
Leukemia; 2003 Jun; 17(6):1058-67. PubMed ID: 12764369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
